[{"address1": "12278 Scripps Summit Drive", "city": "San Diego", "state": "CA", "zip": "92131", "country": "United States", "phone": "858 875 1800", "website": "https://www.fatetherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 181, "companyOfficers": [{"maxAge": 1, "name": "Dr. Bahram  Valamehr M.B.A., Ph.D.", "age": 47, "title": "President, CEO & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 676600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Cindy R. Tahl J.D.", "age": 51, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 644600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Victor  Hong", "title": "Vice President of Corporate Development & Finance", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Francis", "title": "Vice President Of Human Resources & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Henry", "age": 60, "title": "Senior Vice President of Clinical Operations", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tunde  Babalola", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yu  Cai", "title": "Head of Intellectual Property & Assistant General Counsel", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kate  Duvall", "title": "Corporate Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 4, "compensationRisk": 10, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.01, "open": 1.0, "dayLow": 1.0, "dayHigh": 1.12, "regularMarketPreviousClose": 1.01, "regularMarketOpen": 1.0, "regularMarketDayLow": 1.0, "regularMarketDayHigh": 1.12, "payoutRatio": 0.0, "beta": 2.325, "forwardPE": -0.63690484, "volume": 2096502, "regularMarketVolume": 2096502, "averageVolume": 2437080, "averageVolume10days": 1984710, "averageDailyVolume10Day": 1984710, "bid": 1.02, "ask": 1.1, "bidSize": 2, "askSize": 2, "marketCap": 122657320, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 5.92, "priceToSalesTrailing12Months": 9.19815, "fiftyDayAverage": 1.0132, "twoHundredDayAverage": 2.1778, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -34435668, "profitMargins": 0.0, "floatShares": 100120481, "sharesOutstanding": 114633000, "sharesShort": 13339789, "sharesShortPriorMonth": 16374114, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.1164, "heldPercentInsiders": 0.01737, "heldPercentInstitutions": 0.93369, "shortRatio": 5.44, "shortPercentOfFloat": 0.1329, "impliedSharesOutstanding": 114633000, "bookValue": 2.517, "priceToBook": 0.4251093, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -175879008, "trailingEps": -1.49, "forwardEps": -1.68, "enterpriseToRevenue": -2.582, "enterpriseToEbitda": 0.205, "52WeekChange": -0.741688, "SandP52WeekChange": 0.11469197, "quoteType": "EQUITY", "currentPrice": 1.07, "targetHighPrice": 12.0, "targetLowPrice": 2.0, "targetMeanPrice": 5.6875, "targetMedianPrice": 4.5, "recommendationMean": 2.41667, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 240424992, "totalCashPerShare": 2.097, "ebitda": -168276992, "totalDebt": 83329000, "quickRatio": 8.695, "currentRatio": 8.815, "totalRevenue": 13335000, "debtToEquity": 28.893, "revenuePerShare": 0.113, "returnOnAssets": -0.23973, "returnOnEquity": -0.4923, "grossProfits": -102194000, "freeCashflow": -76877376, "operatingCashflow": -123333000, "revenueGrowth": -0.154, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -25.3407, "financialCurrency": "USD", "symbol": "FATE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 5.9406, "regularMarketPrice": 1.07, "cryptoTradeable": false, "marketState": "CLOSED", "shortName": "Fate Therapeutics, Inc.", "longName": "Fate Therapeutics, Inc.", "postMarketChangePercent": 0.934578, "postMarketPrice": 1.08, "postMarketChange": 0.00999999, "regularMarketChange": 0.060000062, "regularMarketDayRange": "1.0 - 1.12", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2437080, "fiftyTwoWeekLowChange": 0.41000003, "fiftyTwoWeekLowChangePercent": 0.6212121, "fiftyTwoWeekRange": "0.66 - 5.92", "fiftyTwoWeekHighChange": -4.85, "fiftyTwoWeekHighChangePercent": -0.8192567, "fiftyTwoWeekChangePercent": -74.1688, "earningsTimestamp": 1747166460, "earningsTimestampStart": 1754909940, "earningsTimestampEnd": 1755259200, "earningsCallTimestampStart": 1715288400, "earningsCallTimestampEnd": 1715288400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.49, "epsForward": -1.68, "epsCurrentYear": -1.262, "priceEpsCurrentYear": -0.8478606, "fiftyDayAverageChange": 0.056800008, "fiftyDayAverageChangePercent": 0.056060012, "twoHundredDayAverageChange": -1.1077999, "twoHundredDayAverageChangePercent": -0.50867844, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.4 - Buy", "firstTradeDateMilliseconds": 1380634200000, "hasPrePostMarketData": true, "corporateActions": [], "postMarketTime": 1747430589, "regularMarketTime": 1747425601, "exchange": "NGM", "messageBoardId": "finmb_39268712", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Fate Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-05-17"}]